Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
September 26, 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at H.C. Wainwright Global Investment Conference
August 30, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
August 07, 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 06, 2018 16:05 ET
|
Kura Oncology, Inc.
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming...
Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer
July 31, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Second Quarter 2018 Financial Results
July 30, 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
July 02, 2018 16:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
June 28, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at JMP Securities Life Sciences Conference
June 14, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
OncoDNA announces screening collaboration with Kura Oncology
May 22, 2018 07:00 ET
|
Kura Oncology, Inc.
- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib- Agreement demonstrates OncoDNA’s biopharma partnership strategy GOSSELIES, Belgium, May 22, 2018 (GLOBE...